Triple-negative breast cancer (TNBC) is a cancer that tests negative for progesterone and estrogen receptors, and excess HER2 protein. This means that the growth of the cancer is not fuelled by the estrogen and progesterone hormones, or by the HER2 protein. So, TNBC does not respond to hormonal therapy medicines or medicines that target HER2 protein receptors.
Colorectal cancer or colon cancer is cancer of the large intestine (colon), which is the final part of the digestive tract. Both colon cancer and rectal cancer can be referred to as colorectal or bowel cancer, but there is a slight difference between the two based on where the cancer begins.
Aimovig (erenumab) is a preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks
There are several ALS medications that are not yet approved in any country and currently under clinical trial. Read about the latest approved treatments.
Here is an overview of each medicine to help guide you and your physician when making a treatment decision for Cystic Fibrosis: 
Here some frequently asked questions and answers that touch on important COVID-19 related updates.
New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.
Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.
Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.
Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.
Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.
MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses.
